search results for: dealforma

Scoop: GSK’s ven­ture team at SR One in talks to spin off from its big phar­ma founder, now un­der new R&D man­age­ment

4 years ago
Financing
Pharma

The good, the bad and lots of just plain old ug­ly: The Q1 num­bers are in

5 months ago

When times got tough, the bio­phar­ma in­dus­try hit the Zoom but­ton and kept things mov­ing at a multi­bil­lion-dol­lar clip

3 years ago
Deals

Q1: A flood of in­vestor cash drove biotech's num­bers to new record highs, and the tor­rent of cash is mov­ing up­stream ...

Last year
Deals

The top 20 pre­clin­i­cal biotech deals ranked by cash up­front re­veals 3 big play­ers — and some ma­jor league stinkers

4 years ago
Deals
Discovery

Top 20 can­cer drug deals: As­traZeneca just changed the glob­al land­scape for deal­mak­ing in on­col­o­gy

4 years ago
Pharma

Or­biMed's TKI play makes its Nas­daq de­but as The­seus prices IPO

11 months ago
Financing

Roche joins the M&A game, buy­ing gene ther­a­py pi­o­neer Spark for $4.3B

4 years ago
Deals
Cell/Gene Tx

UP­DAT­ED: Sanofi buys mR­NA play­er Trans­late Bio for $3.2B. And the price fits a pop­u­lar range for biotech M&A

Last year
Deals

Which big bio­phar­ma play­er should gam­ble $34B on a ripe rare-dis­ease M&A tar­get? An ac­tion-hun­gry top an­a­lyst fills ...

3 years ago
Deals

Is the biotech boom start­ing to fade? The roar­ing ‘20s starts to look a lit­tle fa­tigued. Plus: Top 5 deals, IPOs, ...

11 months ago
Deals
Bioregnum

Who's do­ing deals in the midst of a crip­pling pan­dem­ic? Here are the top 10 play­ers for March

3 years ago
Deals

UP­DAT­ED: Sofinno­va hauls in $548M to build and scale star­tups — as Eu­ro­pean VCs step up their bio­phar­ma game

11 months ago
Financing

Team build­ing. Pipeline re­vamp. For­ward thrust. What does a decade of deals at Gilead tell us about Daniel ...

4 years ago
Pharma

Af­ter a slate of small, tack-on ac­qui­si­tions, is Mer­ck ready to pull the trig­ger on a big M&A deal?

4 years ago
Pharma

Bay­er nabs star biotech Vi­vid­ion with a $2B buy­out and an ‘arms-length’ pact, pulling a part­ner out of the IPO ...

Last year
Deals

The out­lier: 2020 may go down as one of the biggest eco­nom­ic melt­downs in US his­to­ry — but bio­phar­ma is boom­ing

3 years ago
Financing

UP­DAT­ED: An­oth­er three biotechs are set to de­but on Nas­daq as com­bined in­dus­try raise tops $14B

11 months ago
Financing
First page Previous page 1234 Next page Last page

latest

Most read

EMA warns of short­ages of two Boehringer heart drugs due to a spike in de­mand

2 days ago
Pharma
Manufacturing

The End­points 11; blue­bird's $3M gene ther­a­py; Bio­gen tout new neu­ro da­ta; Harsh re­views for can­cer drugs; and more

Yesterday
Weekly

As­traZeneca, Mer­ck cull one Lyn­parza in­di­ca­tion in heav­i­ly pre­treat­ed ovar­i­an can­cer pa­tients

Yesterday
R&D

Fu­ji­film con­tin­ues CD­MO ex­pan­sion, break­ing ground on $435M UK site

Yesterday
Manufacturing

An­oth­er Cipla site lands a Form 483 over clean­ing is­sues and QC con­trols

Yesterday
Pharma
FDA+
see latest stream